BSE: 524654 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Natural Capsules Ltd is a average quality company.
The key valuation ratios of Natural Capsules Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Natural Capsules Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 16.6% | 11.9% | 1.8% | 3.6% | 4.5% | 3.7% | 14.6% | 22.9% | 20.5% | 8.4% | - |
| Value Creation Index ⓘ | 0.2 | -0.2 | -0.9 | -0.7 | -0.7 | -0.7 | 0.0 | 0.6 | 0.5 | -0.4 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 67.3 | 62.1 | 53.6 | 54.8 | 59.8 | 61.6 | 79.5 | 135 | 173 | 154 | 159 |
| Sales YoY Gr. | - | -7.8% | -13.6% | 2.1% | 9.2% | 3% | 29.2% | 69.9% | 28% | -11% | - |
| Adj EPS ⓘ | 8.6 | 5.8 | 1.4 | 1.3 | 2.3 | 0.7 | 7.2 | 14.7 | 19.7 | 7.5 | 5.6 |
| YoY Gr. | - | -32.4% | -76.8% | -1.5% | 75.2% | -72.1% | 1006.2% | 104.7% | 33.9% | -61.9% | - |
| BVPS (₹) ⓘ | 73.3 | 75.8 | 71 | 71.5 | 73 | 73.2 | 81.7 | 118.5 | 133.7 | 141.3 | 158.5 |
| Adj Net Profit ⓘ | 5.5 | 4.1 | 1 | 1 | 1.8 | 0.5 | 5.5 | 13.8 | 18.4 | 7 | 6 |
| Cash Flow from Ops. ⓘ | 5.4 | 3.5 | 1.9 | 5.4 | 2.1 | 7.2 | 5.8 | 5.1 | 20.1 | 5.4 | - |
| Debt/CF from Ops. ⓘ | 1 | 1.6 | 1.6 | 0 | 2.6 | 0.9 | 1.7 | 6.4 | 2.5 | 11.5 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 9.6% | 20.8% | 24.6% | -11% | ||||
| Adj EPS ⓘ | -1.5% | 26.4% | 1.5% | -61.9% | ||||
| BVPSⓘ | 7.6% | 14.1% | 20% | 5.7% | ||||
| Share Price | 14.6% | 46.4% | 15.9% | -20.7% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 12.3 | 8 | 1.9 | 1.9 | 3.2 | 0.9 | 9.3 | 19 | 17.8 | 5.5 | 3.7 |
| Op. Profit Mgn % ⓘ | 17.2 | 15.7 | 9.6 | 10.1 | 8.5 | 8.9 | 14.5 | 18.1 | 20.1 | 12.9 | 12.1 |
| Net Profit Mgn % ⓘ | 8.2 | 6.6 | 1.9 | 1.9 | 3 | 0.8 | 6.9 | 10.2 | 10.7 | 4.6 | 3.6 |
| Debt to Equity ⓘ | 0.1 | 0.1 | 0.1 | 0 | 0.1 | 0.1 | 0.2 | 0.4 | 0.4 | 0.5 | 0.1 |
| Working Cap Days ⓘ | 146 | 201 | 278 | 273 | 253 | 246 | 231 | 182 | 181 | 239 | 108 |
| Cash Conv. Cycle ⓘ | 95 | 131 | 179 | 172 | 161 | 165 | 97 | 31 | 42 | 83 | 30 |
Sales growth is growing at healthy rate in last 3 years 24.60%
Return on Equity has declined versus last 3 years average to 3.70%
Net Profit has been subdued in last 3 years 1.46%
Sales growth is not so good in last 4 quarters at 0.75%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 5.6 | 2.1 |
| TTM Sales (₹ Cr.) | 159 | 161 |
| BVPS (₹.) ⓘ | 158.5 | 225.9 |
| Reserves (₹ Cr.) ⓘ | 154 | 223 |
| P/BV ⓘ | 1.66 | 1.16 |
| PE ⓘ | 47.02 | 125.19 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 255.00 / 403.00 |
| All Time Low / High (₹) | 0.08 / 679.00 |
| Market Cap (₹ Cr.) | 271 |
| Equity (₹ Cr.) | 10.3 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 67 | 62 | 54 | 55 | 60 | 62 | 80 | 135 | 173 | 154 |
| Operating Expenses ⓘ | 56 | 52 | 49 | 49 | 55 | 56 | 68 | 111 | 138 | 134 |
| Manufacturing Costs | 14 | 13 | 13 | 12 | 15 | 14 | 14 | 22 | 28 | 30 |
| Material Costs | 28 | 25 | 24 | 24 | 26 | 28 | 37 | 60 | 79 | 77 |
| Employee Cost | 5 | 6 | 5 | 5 | 6 | 6 | 7 | 8 | 10 | 11 |
| Other Costs ⓘ | 9 | 9 | 6 | 9 | 8 | 8 | 10 | 21 | 22 | 16 |
| Operating Profit ⓘ | 12 | 10 | 5 | 6 | 5 | 5 | 11 | 24 | 35 | 20 |
| Operating Profit Margin (%) | 17.2% | 15.6% | 9.6% | 10.1% | 8.5% | 8.8% | 14.0% | 18.1% | 20.1% | 12.9% |
| Other Income ⓘ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 4 |
| Interest ⓘ | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 4 | 5 |
| Depreciation ⓘ | 4 | 4 | 4 | 4 | 3 | 4 | 4 | 5 | 7 | 9 |
| Exceptional Items ⓘ | 0 | 0 | -1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 8 | 6 | 0 | 2 | 2 | 1 | 9 | 19 | 26 | 10 |
| Tax ⓘ | 2 | 2 | 0 | 1 | 0 | 1 | 2 | 5 | 7 | 3 |
| Profit After Tax | 6 | 4 | 1 | 1 | 2 | 1 | 7 | 14 | 19 | 8 |
| PAT Margin (%) | 8.4% | 7.0% | 1.2% | 2.0% | 3.2% | 1.4% | 8.7% | 10.3% | 11.1% | 5.1% |
| Adjusted EPS (₹) | 8.8 | 6.1 | 0.8 | 1.5 | 2.5 | 1.1 | 9.1 | 19.9 | 20.7 | 8.4 |
| Dividend Payout Ratio (%) | 14% | 20% | 99% | 56% | 32% | 44% | 9% | 5% | 5% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 47 | 54 | 54 | 54 | 55 | 56 | 62 | 83 | 124 | 132 |
| Share Capital ⓘ | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 9 | 9 |
| Reserves ⓘ | 42 | 48 | 48 | 48 | 49 | 49 | 56 | 76 | 115 | 123 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 5 | 6 | 3 | 0 | 5 | 6 | 10 | 31 | 45 | 56 |
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 23 | 26 |
| Short Term Debt | 5 | 6 | 3 | 0 | 5 | 6 | 10 | 16 | 22 | 29 |
| Trade Payables | 6 | 10 | 11 | 12 | 8 | 7 | 16 | 16 | 27 | 30 |
| Others Liabilities ⓘ | 5 | 8 | 4 | 5 | 4 | 6 | 9 | 13 | 14 | 14 |
| Total Liabilities ⓘ | 63 | 77 | 71 | 71 | 73 | 75 | 97 | 143 | 210 | 231 |
Fixed Assets | ||||||||||
| Gross Block | 56 | 61 | 61 | 61 | 66 | 70 | 83 | 108 | 146 | 152 |
| Accumulated Depreciation | 27 | 31 | 35 | 40 | 42 | 46 | 49 | 45 | 53 | 61 |
| Net Fixed Assetsⓘ | 29 | 30 | 26 | 22 | 24 | 24 | 35 | 63 | 93 | 91 |
| CWIP ⓘ | 2 | 0 | 0 | 1 | 2 | 2 | 3 | 1 | 0 | 2 |
| Investmentsⓘ | 0 | 5 | 5 | 5 | 5 | 6 | 0 | 0 | 20 | 23 |
| Inventories | 5 | 10 | 8 | 8 | 4 | 5 | 7 | 5 | 8 | 18 |
| Trade Receivables | 23 | 28 | 28 | 31 | 32 | 30 | 27 | 26 | 52 | 54 |
| Cash Equivalents | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 3 | 2 | 9 |
| Others Assetsⓘ | 3 | 4 | 4 | 3 | 4 | 7 | 25 | 46 | 34 | 36 |
| Total Assets ⓘ | 63 | 77 | 71 | 71 | 73 | 75 | 97 | 143 | 210 | 231 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 5 | 3 | 2 | 5 | 2 | 7 | 6 | 5 | 20 | 5 |
| PBT ⓘ | 8 | 6 | 0 | 2 | 2 | 1 | 9 | 19 | 26 | 10 |
| Adjustment ⓘ | 5 | 5 | 4 | 5 | 4 | 5 | 3 | 6 | 10 | 12 |
| Changes in Working Capital ⓘ | -5 | -6 | -3 | -1 | -3 | 1 | -4 | -16 | -10 | -15 |
| Tax Paid ⓘ | -2 | -2 | 0 | 0 | -1 | -1 | -2 | -5 | -5 | -2 |
| Cash Flow From Investing Activity ⓘ | -4 | -8 | 0 | -1 | -7 | -6 | -9 | -30 | -55 | -11 |
| Capex | -4 | -5 | 0 | -1 | -7 | -5 | -16 | -31 | -36 | -8 |
| Net Investments | 0 | -5 | 0 | 0 | 0 | -1 | 8 | 0 | -20 | -3 |
| Others ⓘ | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Cash Flow From Financing Activityⓘ | -1 | 4 | -2 | -4 | 4 | -1 | 3 | 27 | 34 | 7 |
| Net Proceeds from Shares ⓘ | 1 | 3 | 3 | 0 | 0 | 0 | 0 | 8 | 23 | 1 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 13 |
| Interest Paid ⓘ | -1 | 0 | -1 | 0 | 0 | -1 | 0 | -2 | -4 | -5 |
| Dividend Paid ⓘ | -1 | -1 | -1 | -1 | -1 | -1 | 0 | -1 | -1 | -1 |
| Others ⓘ | -1 | 2 | -3 | -3 | 5 | 0 | 3 | 21 | 0 | 0 |
| Net Cash Flow ⓘ | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 1 | -1 | 2 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 12.67 | 8.65 | 1.17 | 2.05 | 3.5 | 1.54 | 11.8 | 19.22 | 18.54 | 6.1 |
| ROCE (%) | 16.57 | 11.93 | 1.77 | 3.63 | 4.51 | 3.71 | 14.57 | 22.93 | 20.5 | 8.44 |
| Asset Turnover Ratio | 1.17 | 0.95 | 0.72 | 0.77 | 0.83 | 0.83 | 0.93 | 1.12 | 0.98 | 0.7 |
| PAT to CFO Conversion(x) | 0.83 | 0.75 | 2 | 5 | 1 | 7 | 0.86 | 0.36 | 1.05 | 0.63 | Working Capital Days |
| Receivable Days | 106 | 140 | 192 | 198 | 194 | 185 | 131 | 72 | 83 | 125 |
| Inventory Days | 22 | 41 | 61 | 52 | 37 | 28 | 27 | 15 | 14 | 31 |
| Payable Days | 67 | 115 | 155 | 173 | 140 | 99 | 112 | 98 | 100 | 135 |
Natural Capsules is a public limited company established in the year 1993.The company is a well-equipped modern manufacturing plant to manufacture hard gelatin capsule shells, Hard cellulose capsule shells and pharmaceutical dosage forms in capsule dosage form.
The company meets the statutory requirements as laid down by the authorities in respect to cGMP and cGLP practices. Since its inception, Natural Capsules has ensured to provide turnkey solutions to all its customers. NCL has evolved and strengthened its endeavors by constantly innovating through its excellent products. With a mission to enable ‘Technology Assisted Business Transformation’, NCL ensure to deliver the best products with a technological edge.
The main objective of the company is to manufacture and market hard gelatin capsule shells and hard cellulose capsule shells (both printed and unprinted). These capsules are sold in the domestic market and also exported to several countries. The logical integration of NCL hard shell manufacturing to formulation was initiated in the year 1998.
The company is also engaged in formulating the pharmaceutical dosage forms in capsule dosage form, both pharma and neutraceutical products. The company is fully committed to upgrade its facilities on a continuous basis to meet the requirements of national and international standards, cGMP and cGLP practices. Natural Capsule has been serving the pharmaceutical industry over a decade, comprising of two units – one at Bangalore and other at Pondicherry.
The pharmaceutical and dietary supplement industries count on Natural Capsules to supply hard two-piece gelatin and cellulose capsules. With manufacturing sites at Bangalore and Pondicherry, they are serving customers on quick service no matter where they are located. For the past 12 years, with the greatest respect to the customers, Natural Capsules has dedicated itself to the production of the highest quality capsules.
Products and services offered by the company:
Products:
Services:
Achievements/ recognition:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
